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Intranasal Midazolam versus Rectal Diazepam for the Management
of Canine Status Epilepticus: A Multicenter Randomized
Parallel-Group Clinical Trial
M. Charalambous , S.F.M. Bhatti, L. Van Ham, S. Platt, N.D. Jeﬀery, A. Tipold, J. Siedenburg ,
H.A. Volk, D. Hasegawa, A. Gallucci, G. Gandini, M. Musteata, E. Ives, and A.E. Vanhaesebrouck
Background: Intranasal administration of benzodiazepines has shown superiority over rectal administration for terminat-
ing emergency epileptic seizures in human trials. No such clinical trials have been performed in dogs.
Objective: To evaluate the clinical eﬃcacy of intranasal midazolam (IN-MDZ), via a mucosal atomization device, as a
ﬁrst-line management option for canine status epilepticus and compare it to rectal administration of diazepam (R-DZP) for
controlling status epilepticus before intravenous access is available.
Animals: Client-owned dogs with idiopathic or structural epilepsy manifesting status epilepticus within a hospital environ-
ment were used. Dogs were randomly allocated to treatment with IN-MDZ (n = 20) or R-DZP (n = 15).
Methods: Randomized parallel-group clinical trial. Seizure cessation time and adverse eﬀects were recorded. For each
dog, treatment was considered successful if the seizure ceased within 5 minutes and did not recur within 10 minutes after
administration. The 95% conﬁdence interval was used to detect the true population of dogs that were successfully treated.
The Fisher’s 2-tailed exact test was used to compare the 2 groups, and the results were considered statistically signiﬁcant if
P < .05.
Results: IN-MDZ and R-DZP terminated status epilepticus in 70% (14/20) and 20% (3/15) of cases, respectively
(P = .0059). All dogs showed sedation and ataxia.
Conclusions and Clinical Importance: IN-MDZ is a quick, safe and eﬀective ﬁrst-line medication for controlling status
epilepticus in dogs and appears superior to R-DZP. IN-MDZ might be a valuable treatment option when intravenous access
is not available and for treatment of status epilepticus in dogs at home.
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Emergency epileptic seizures, including status epilep-ticus and severe cluster seizures, commonly occur
in dogs either at home or during hospitalization.1,2 Sta-
tus epilepticus can be caused by toxic and metabolic
causes or structural brain disease. It can also occur as a
manifestation of idiopathic epilepsy,3 with an estimated
20–60% of aﬀected dogs experiencing at least 1 episode
of status epilepticus during their lifetime.2,4
Status epilepticus is a life-threatening condition in
dogs with an estimated case fatality rate of 25.3–
38.5%5,6 and requires immediate management in order
to avoid primary and secondary permanent damage to
the brain7–11 or other severe systemic complications
such as hyperthermia, acidosis, disseminated intravascu-
lar coagulation, and renal and cardiopulmonary
failure.12 Status epilepticus can shorten a dog’s lifespan
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by 2 years due to the increased likelihood for euthana-
sia.2 Therefore, eﬀective ﬁrst-line management of emer-
gency seizures both at home and in the hospital
environment is vital and potentially life-saving.
Benzodiazepines, such as diazepam (DZP) and mida-
zolam (MDZ), are commonly used as a ﬁrst-line man-
agement option for status epilepticus in both humans
and dogs10,13–16 and can be eﬀective at low doses.17
Rectal (R), intranasal (IN), intramuscular (IM), buccal
or sublingual administration may be useful, especially
when intravenous access (IV) is not available.18
DZP is commonly used for the management of emer-
gency seizures.19–21 IV administration of DZP provides
good pharmacokinetic properties20 and is commonly
used by veterinarians as a ﬁrst- or second-line medica-
tion. R-DZP is a relatively easy and quick method by
which owners or veterinarians can attempt to terminate
acute seizures when IV access is not available. Based on
pharmacokinetic studies, injectable DZP solution
administered per rectum has been recommended for the
management of emergency seizures in dogs.15,21,22 How-
ever, in another study, R-DZP did not result in pre-
sumed therapeutic plasma concentrations quickly
enough to be eﬀective for the management of emer-
gency seizures.23 On the other hand, in 1 clinical trial,
R-DZP was considered eﬀective for treating canine gen-
eralized cluster seizures.24 Pharmacokinetic studies indi-
cate that MDZ, administered via IV and IM routes,
might be useful to treat seizures, but that rectal applica-
tion was unlikely to be eﬀective.25
Several human clinical trials have been performed to
evaluate IN-MDZ in children and adults with emergency
seizures, with or without comparison to R-DZP. These
have shown that IN-MDZ is an eﬀective and safe medi-
cation within the hospital and home settings.18,26–38 In
dogs, only pharmacokinetic studies have been performed
and showed that DZP,20,39 MDZ,40,41 triazolam, and
ﬂurazepam41 were eﬃciently absorbed and rapidly
reached maximum serum concentrations after IN admin-
istration. To our knowledge, this study is the ﬁrst clini-
cal trial to evaluate the eﬃcacy of IN administration of
a benzodiazepine in dogs with status epilepticus. The
primary objective of this study was to evaluate the clini-
cal eﬃcacy of IN-MDZ as a ﬁrst-line management
option for status epilepticus and compare IN-MDZ to
the widely used R-DZP for controlling emergency sei-
zures when there is no IV access. Toward that goal, a
nasal mucosal atomization device (MAD) (Fig 1), which
converted the liquid drug into a ﬁne mist, was used to
eﬀectively deliver the MDZ into the nasal cavity. The
study was performed within a hospital environment with
the results anticipated to form the basis for using IN-
MDZ for the treatment of emergency seizures at home.
Materials and Methods
Evaluation of Clinical Eﬃcacy and Safety Under Field
Conditions
The study was conducted as an open-labeled randomized paral-
lel-group clinical trial with client-owned animals in combination
with good clinical practice. It aimed to compare the clinical eﬀec-
tiveness of IN-MDZ, delivered by the MAD, to R-DZP, as a ﬁrst-
line treatment option for canine status epilepticus. The study was
approved by the universities’ ethical committees (reference num-
ber, CR87). An animal test certiﬁcate from the Veterinary Medici-
nes Directorate was obtained for the use of IN-MDZ. Owner
consent and information forms were provided and signed by the
owners. The dogs were under constant observation and monitoring
throughout the study.
Study Population
Dogs with status epilepticus without age, breed, or sex limita-
tions were considered for enrollment in the study. Dogs with idio-
pathic and structural epilepsy and epilepsy of unknown origin
were included, but those with known reactive seizures (i.e, meta-
bolic or toxic causes) were excluded. Dogs with generalized or
focal epileptic seizures characterized clinically by any type of
motor activity (e.g, tonic, clonic, tonic-clonic, myoclonic) were
included. As status epilepticus is considered a medical emergency,
diagnostic investigation (if diagnosis was not already known) fol-
lowed the initial treatment and stabilization of each case. There-
fore, dogs were ﬁrst included in the trial and treated but, if the
subsequent diagnostic tests indicated reactive seizures, dogs were
excluded from the study. Dogs were excluded from the study if
any medications had been administered before 5 minutes of con-
tinuous epileptic seizure activity had passed.
Fig 1. Mucosal administration device (MAD). The device consists
of a syringe (1 mL or 3 mL) and the, attached to the syringe, ato-
mizer. The latter turns the medication into a ﬁne mist (30–
100 lm).
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The classiﬁcation of epilepsy types deﬁned by etiology and the
classiﬁcation by seizure semiology, as well as the approach for the
diagnosis of idiopathic and structural epilepsy, epilepsy of
unknown origin, and reactive seizures, was based on the recom-
mendations of the International Veterinary Epilepsy Task Force
(IVETF) consensus reports42,43. For the diagnosis of idiopathic
epilepsy cases, the Tier classiﬁcation was used to provide a conﬁ-
dence level scale.43 Tier I and Tier III provided the weakest and
strongest level of conﬁdence for the diagnosis of idiopathic epi-
lepsy, respectively. Status epilepticus was deﬁned as a continuous
epileptic seizure with a duration of more than 5 minutes, or 2 or
more discrete epileptic seizures between which there was incom-
plete recovery of consciousness.12,42
Procedure
The procedure is summarized as a ﬂowchart (Fig 2). Animals
arriving at the participating hospital and hospitalized patients with
status epilepticus were recruited to the trial. In the ﬁrst scenario, it
was assumed that dogs had been already seizuring for a period
longer than 5 minutes, unless indicated otherwise by the owner or
referring veterinarian, and therefore, the protocol process was
immediately initiated for those patients. For hospitalized patients,
a diﬀerent procedure was applied to ensure that only dogs for
which seizure activity had been occurring for greater than 5 min-
utes were enrolled.44 Speciﬁcally, the veterinary student, nurse, or
technician in the ward that was observing and monitoring the
patients called the on-call or onsite veterinarian after 3 minutes of
observed continuous epileptic seizure activity. After 5 minutes of
recorded seizure activity, or if the dog was still seizing upon the
veterinarian’s arrival and therefore it was assumed that 5 minutes
had passed (unless indicated otherwise), the protocol process was
initiated. Standardized sheets were used to record the relevant
information needed to assess the outcomes. The veterinarian was
responsible for preparing and administering the medication, and
the nurse, technician, or student was responsible for handling the
stopwatch and recording the relevant times. Recording of the
appropriate information on the sheets was performed by the vet-
erinarian or the assistant under veterinary supervision.
Dogs were assigned into the 2 groups (IN-MDZ and R-DZP)
using randomized sealed envelopes. The envelopes were randomly
numbered and opened following a numeric sequence starting from
the envelope number one. A box containing all the materials
required for the trial (i.e, atomization devices, medications, record
and information sheets, randomization envelopes, stopwatch) was
kept in a safe place within the intensive care unit (ICU) or similar
area in each center in order to achieve easy and rapid access to
the materials. MDZ injectable solution (5 mg/mL) at the dose of
0.2 mg/kg was administered intranasally by the use of the MAD.
If there were excessive nasal secretions, these were quickly
removed before administration using gauze. If the MDZ’s adminis-
tered dose was greater than 1 milliliter, then the drug was adminis-
tered into the nasal cavities via both nostrils rather than only one
to prevent underdosing through drug outﬂow. A chart reporting
the total amount of the drug in milliliters (including the MAD
device’s dead space) per kilogram was provided to each center by
the primary author with the aim of increasing the practicality and
feasibility of the drug administration process. Similarly, DZP
injectable solution (5 mg/mL) at the dose of 1 mg/kg was given
per rectum with the aid of a standard needleless syringe that was
applied as deep as possible into the rectum. A chart reporting the
total dose in milliliters for dogs between 0.5 and 70 kg was also
provided. After administration of the allocated drug, a catheter
was placed, if not done previously, to provide IV access. All dogs
were treated within a hospital environment, and the dogs were
hospitalized in an ICU, or similar area, for continuous observation
and monitoring for at least 1 hour after benzodiazepine adminis-
tration. In all, observation was performed for at least 24 hours.
Outcomes Assessment
Primary Outcome. The aim of the study was the evaluation of
the clinical eﬃcacy of the IN-MDZ or R-DZP. This was assessed
by the “seizure cessation” time (i.e, time between drug administra-
tion and seizure cessation) and “seizure relapse” time (i.e, time
between seizure cessation and the next seizure). Successfulness of
treatment was determined as follows:
Successful Cases. Treatment was considered successful if the
seizure cessation time was less than 5 minutes and the seizures did
not relapse or the seizure relapse time was at least 10 minutes.30
Seizure cessation was deﬁned as the termination and absence of
visible seizure-related motor activity. No other drug was adminis-
tered during that period.
Unsuccessful Cases. Treatment was considered unsuccessful
if the seizure cessation time was greater than 5 minutes or the
seizure relapse time was less than 10 minutes after the benzodi-
azepine administration. In this case, the protocol was no longer
applicable for the patient, and IV DZP 0.5–1 mg/kg was immedi-
ately administered. Time needed for IV DZP to cease the epileptic
seizures was recorded, if applicable. Further additional antiepilep-
tic drug therapy (e.g, levetiracetam, phenobarbital, potassium bro-
mide, propofol) was chosen at the discretion of the clinician in
charge and the cascade used in each individual hospital.
Secondary Outcomes.
(a) “Call to doctor” time, that is, time period between the call and
arrival of the veterinary surgeon. This was expressed in sec-
onds and presented as median and range values for each
group.
(b) “Doctor to drug” time, that is, time needed by the veterinary
surgeon for the preparation and administration of the drug.
This was expressed in seconds and presented as median and
range values for each group.
(c) Complications and adverse eﬀects. Heart rate and rhythm, res-
piratory rate and pattern, blood pressure (by use of Doppler),
and oxygen saturation (by use of pulse oximetry) were mea-
sured 10 (T10) and 60 (T60) minutes after drug administration.
Any other unusual events or adverse eﬀects, such as dyspnoea,
sneezing, vomiting, as well as sedation or ataxia that occurred
within 60 minutes, were recorded. A visual analogue scale was
provided to determine levels of sedation and ataxia at 0 (T0),
10 (T10), and 60 (T60) minutes after initial administration.
Speciﬁcally, a 9.0 centimeter horizontal line was drawn on the
record sheets by the primary author. This was used by the
attending clinician to intersect a second perpendicular line to
indicate the subjective severity of sedation and ataxia on 2 sep-
arate sheets. The point at “0” centimeters was considered as
“bright, alert, and responsive dog” and “dog with normal gait
and stance”. The point at “9.0” centimeters was considered as
“unconscious and nonresponsive dog” and “dog unable to
stand or walk”. The primary author assessed this visual ana-
logue scale as marked by the observers based on the following
assessment: “0.1–2.9”, “3.0–5.9”, “6.0–8.9” centimeters corre-
sponded to mild, moderate, and severe degree of sedation or
ataxia.
(d) Ease of administration. Any concerns were recorded by the
attending clinician, with examples including but not limited to
the administrator’s fear of being bitten or injured by the seiz-
ing animal and diﬃculties in applying the MAD device into
the nostrils or the syringe into the anus.
(e) Further information (if known or applicable), including the
cause of seizures, duration of seizures before drug
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administration, number of previous seizures over the last
24 hours, AEDs administered before status epilepticus as well
as during between 10 and 60 minutes after the IN-MDZ or R-
DZP administration, was recorded.
Statistical Analysis
The primary outcome was assessed by the number of dogs in
each group for which treatment was recorded as successful. The
true population of dogs in each group that were successfully
treated was calculated based on the 95% conﬁdence interval
(95% CI) by standard methods.45 The Fisher’s 2-tailed exact
test was used to detect statistical diﬀerences between the 2
groups. Results were considered statistically signiﬁcant at a sig-
niﬁcance level of P < .05. Sample size calculation for an alpha
cutoﬀ of 0.05 and a power of 80% was based on the data from
a relevant human-based trial28 and resulted in 36 dogs per
group. An interim analysis was also performed to assess whether
or not a signiﬁcant diﬀerence could be detected between the
groups.
Results
Signalment and Baseline Characteristics of Study
Subjects
The recruited dogs represented multiple breeds, both
sexes and a wide range of ages at study entry (Table 1).
Disease Characterization
Thirty-eight dogs were initially included in the trial
and treated. Three of these dogs were subsequently
excluded because they manifested reactive seizures due
to hypoglycemia (1 dog) and presumed intoxication (2
dogs). For 2 dogs (7.4 and 8.2 years old at seizure onset),
there was no conﬁrmed diagnosis of the cause of seizures
(focal structural brain lesion was suspected, but MRI
and/or CSF analysis was not performed for conﬁrma-
tion). These dogs were included in the study because the
history, hematology and serum biochemistry evaluation,
Fig 2. Flowchart presenting a summary of the protocol.
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and urinalysis showed no evidence of intoxication or
metabolic disorder. Thirty-ﬁve cases were ﬁnally
included in the trial (20 in IN-MDZ group and 15 in R-
DZP group) and analyzed.
These cases represented dogs with idiopathic epilepsy
(21/35, 60%), structural epilepsy (12/35, 34%), or epi-
lepsy of unknown origin (2/35, 6%). The ﬁnal diagnoses
in cases with structural epilepsy were neoplasia (7/12,
58%) or meningoencephalitis of unknown origin
(MUO) (5/12, 42%), after brain MRI and/or CSF anal-
ysis. The majority of the dogs diagnosed with idiopathic
epilepsy were classiﬁed as Tier II conﬁdence level (11/
21, 52%), followed by Tier I (10/21, 48%). Thirty-three
dogs presented with generalized tonic and/or clonic sei-
zures and 2 dogs with focal (facial motor activity) status
epilepticus seizure activity. The latter were allocated in
the IN-MDZ group. Further details for each group are
provided in Table 1.
Primary Outcome
The primary outcome for each dog and treatment
group is summarized in the text and provided in detail
in Table 2 and Tables S1 and S2.
IN-MDZ Group
For the successful cases, the median “seizure cessa-
tion” time was 47 seconds (range, 6–280). In 3/14
(21%) of the successful cases, there was no relapse of
the seizures. For the remaining 11/14 (79%) of the
cases, the median “seizure relapse” time was 904 sec-
onds (range, 612–1146).
R-DZP Group
For the successful cases, the median “seizure cessa-
tion” time was 214 seconds (range, 204–290). All of the
successful cases relapsed. The median “seizure relapse”
time was 645 seconds (range, 638–672).
IN-MDZ versus R-DZP
Based on the ﬁsher’s 2-tailed exact test, there was a
statistically signiﬁcant diﬀerence (P = .0059) between
the 2 groups. For the idiopathic epilepsy cases in partic-
ular, IN-MDZ was signiﬁcantly more eﬀective com-
pared to R-DZP (P = .018). Therefore, dogs treated
with IN-MDZ were more likely to show seizure cessa-
tion compared to dogs treated with R-DZP.
Secondary Outcomes
The secondary outcomes for each dog and treatment
group are summarized in the text and provided in detail
in Table 2 and Tables S1, S2, and S3.
IN-MDZ Group
The median “call to doctor” and “doctor to drug”
time was 56 seconds (range, 12–182) and 29 seconds
(range, 14–185), respectively. For the unsuccessful
cases, IV DZP was administered in 3/6 (50%) of
those and the median “seizure cessation” time was
45 seconds (range, 40–240). For all the cases, the
most common AEDs used between 10 and 60 minutes
after IN-MDZ administration were IV levetiracetam
and/or IV or IM phenobarbital, followed by IV DZP
Table 1. Details of the dogs’ basic characteristics in each group.
Groups IN-MDZ R-DZP
Breed Crossbreeds (48%), Labrador Retriever (2%), Golden
Retrievers (11%), German Shepherd dogs (15%),
Beagles (7%), Boxers (3%), English Setters (2%),
Alaskan Malamute (2%), Border Collies (4%), Pugs
(1%), and Pekingese dogs (5%)
Crossbreeds (41%), Labrador Retriever (12%),
Golden Retrievers (10%), German Shepherd
dogs (13%), Beagles (5%), Boxers (2%),
Dogo Argentino (1%), English Setters (3%),
Shetland Sheepdog (4%), Border Collies (9%)
Age Median, 5.1 (range 0.5–7 years) Median, 4.8 (range 0.9–6.8 years)
Sex 12 males (60%) and 8 females (40%) 8 males (53%) and 7 females (47%)
Epilepsy
classiﬁcation
13 dogs (65%) with idiopathic epilepsy, 6 dogs (30%)
with structural epilepsy (neoplasia, 4 dogs; MUO, 2
dogs) and 1 dog (5%) with epilepsy of unknown origin
8 dogs (53%) with idiopathic epilepsy, 6 dogs
(40%) with structural epilepsy (neoplasia, 3
dogs; MUO, 3 dogs), and 1 dog (7%) with
epilepsy of unknown origin
Chronic/
Maintenance AEDs
9 dogs (45%) were not receiving chronic antiepileptic
medication. The remaining dogs were receiving
phenobarbital monotherapy (3 dogs; 15%), phenobarbital/
potassium bromide combination therapy (2 dogs; 10%),
phenobarbital/potassium bromide/levetiracetam combination
(4 dogs; 20%), levetiracetam monotherapy (1 dog; 5%),
imepitoin monotherapy (1 dog; 5%)
5 dogs (33%) were not receiving chronic
antiepileptic medication. The remaining dogs
were receiving phenobarbital monotherapy
(4 dogs; 27%), phenobarbital/potassium
bromide combination therapy (5 dogs; 33%),
phenobarbital/potassium bromide/
levetiracetam combination therapy
(1 dog; 7%)
Cluster epilepsy (before
occurrence of
status epilepticus)
Twelve dogs (60%) Seven dogs (47%)
AEDs, antiepileptic drugs; DZP, diazepam; IN, intranasal; MDZ, midazolam; R, rectal.
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and constant rate infusion (CRI) MDZ. Severe seda-
tion and ataxia were recorded for all the dogs that
were worse at T10 and T60, in particular, compared
to T0. No signs of respiratory (e.g, dyspnea, bradyp-
nea, cough, cyanosis) or cardiovascular (e.g, arrhyth-
mias, hypotension/hypertension, cardiac arrest)
dysfunction were reported in any of the dogs. A brief
episode of sneezing during or after administration of
IN-MDZ and mild diﬃculties in regard to the appli-
cation of the MAD were reported in a few dogs. No
nasal discharge was reported before and/or during
administration.
R-DZP Group
The median “call to doctor” and “doctor to drug”
time was 68 seconds (range, 25–180) and 16 seconds
(range, 8–38). For the unsuccessful cases, IV DZP
was administered in 10/12 (83%) of those and was
unsuccessful in 2/10 (20%) cases. The median “seizure
cessation” time after IV DZP was 32 seconds (range,
17–52). The most common AEDs used between 10
and 60 minutes after R-DZP administration were sim-
ilar to the IN-MDZ group. Severe sedation and
ataxia were detected for all the dogs and, as for IN-
MDZ, the degree of sedation and ataxia was worse
at T10 and T60 compared to at T0. No signs of res-
piratory (e.g, dyspnea, bradypnea, cough, cyanosis) or
cardiovascular (e.g, arrhythmias, hypotension/hyper-
tension, cardiac arrest) dysfunction were reported in
any of the dogs. Diﬃculties during administration
were reported in a few dogs in regard to insertion of
the syringe into the rectum during severe tonic/clonic
seizure activity.
Discussion
The results of the present study indicate that IN
administration of MDZ is likely to be an eﬀective and
safe method for short-term management of emergency
seizures in dogs. In this study, IN-MDZ was signiﬁ-
cantly more eﬀective than R-DZP for terminating status
epilepticus in a hospital environment. It is likely that
this ﬁnding could be extrapolated to at-home treatment
of emergency seizures before hospital admittance and,
as such, IN-MDZ might be a more appropriate and
eﬀective prehospital seizure management method than
R-DZP.
Studies compared IN-MDZ to R-DZP in humans
and showed statistically signiﬁcant superiority of
IN-MDZ for cessation of seizures.18,26,28 In one study,
IN-MDZ was compared to R-DZP in 23 and 22
patients, respectively, within the emergency department
setting, and it was found that IN-MDZ was signiﬁ-
cantly more likely to successfully control seizure activity
within the ﬁrst 10 minutes compared to R-DZP.28 In
another study, IN-MDZ was compared to R-DZP in a
total number of 46 children and found seizure control
to be faster with IN-MDZ.26 In a third study, IN-MDZ
was compared to R-DZP in 39 and 18 children, respec-
tively, and showed superiority of IN-MDZ over R-DZP
for seizure control.18 However, a larger study did not
Table 2. Summary of the primary and secondary outcomes.
IN-MDZ R-DZP
Successful cases Total
14/20
(70%)
IE
11/13
(85%)
SE
2/6 (33%) (MUO,
0%; Neoplasia, 50%; of
total number of SE cases)
EUO
1/1
(100%)
Total
3/15
(20%)
IE
2/8
(25%)
SE
1/6
(17%) (Neoplasia,
33%; of total number
of SE cases)
EUO
0 (0%)
95% CI:
48–85%
95% CI:
6.6–43%
“Seizure cessation” time
(mins) (median, range)
0.8 minutes (0.1–5) 3.5 minutes (3.4–5)
“Seizure cessation” time
(mins) after IV DZP
(unsuccessful cases)
(median, range)
0.75 minutes (0.6–4) 0.5 minutes (0.3–0.9)
“Seizure relapse” time
(mins) (median, range)
15 minutes (10–19) 10.8 minutes (10.6–11.2)
“Call to doctor” (mins)
(median, range)
1 minute (0.2–3) 1.1 minutes (0.4–3)
“Doctor to drug” (mins)
(median, range)
0.5 minutes (0.2–3) 0.3 minutes (0.1–0.6)
Adverse eﬀects (within
60 minutes of drug
administration)
Severe sedation and ataxia in all dogs and a brief
episode of sneezing in 7/20 (35%) dogs
Severe sedation and
ataxia in all dogs
Diﬃculties in
administration
Mild diﬃculties in applying the MAD in 2/20 (10%)
dogs
Diﬃculties in applying
the syringe in 2/15 (13%) dogs
CI, conﬁdence interval; DZP, diazepam; EUO, epilepsy of unknown origin; IE, idiopathic epilepsy; IN, intranasal; MDZ, midazolam;
SE, structural epilepsy; R, rectal.
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demonstrate a signiﬁcant diﬀerence in cessation of sei-
zures between IN-MDZ and R-DZP.30 Ease of adminis-
tration was considered higher in IN-MDZ group in this
study, although this factor is likely to be signiﬁcantly
diﬀerent for human trials compared to canine patients.
Interestingly, IN-MDZ has also been compared to IV
DZP, and it was shown that both medications were
eﬀective and safe, although IV DZP was rather quicker
in controlling seizures.33,35 In a recent human systematic
review/meta-analysis, non-IV administration of MDZ,
including IN-MDZ, was as eﬀective and safe as IV
DZP in terminating early status epilepticus.46 In the
present study, the “seizure cessation” time of IN-MDZ
(median, 47 seconds) was relatively similar to IV DZP
(median, 32–45 seconds). However, this result should be
interpreted with caution because IV DZP was adminis-
tered only after the initial administration of IN-MDZ
or R-DZP and in a small number of the unsuccessfully
treated dogs.
IN administration of 0.2 mg/kg MDZ40 and 0.5 mg/
kg DZP20 has shown favorable pharmacokinetic proper-
ties and bioavailability in studies on healthy dogs, and
it has been suggested that both could be useful for
treatment of seizures in dogs by owners or when IV
access is not available. Although IN-DZP could poten-
tially be as eﬀective as IN-MDZ for dogs with status
epilepticus, this was not evaluated in the current clinical
trial. Instead, based on the canine pharmacokinetic
studies and human trials mentioned, IN-MDZ was cho-
sen in this study. Also, MDZ is a water-soluble medica-
tion (in contrast to DZP) and small enough (i.e,
molecular weight of 325.8 Daltons) to permeate nasal
mucosa.47,48 The results indicated that it might be eﬀec-
tive as a ﬁrst-line medication for ceasing emergency sei-
zures and appeared superior to R-DZP for this role. It
was also demonstrated that the majority of the dogs
with structural epilepsy were unsuccessful cases. How-
ever, the small number of dogs with structural epilepsy
and the diﬀerence in proportion of dogs with structural
epilepsy between the groups preclude deﬁnite conclu-
sions. In comparison, the majority of the dogs with
idiopathic epilepsy were successful (9/12, 75%). In addi-
tion, the 2 dogs that manifested focal seizures and trea-
ted with IN-MDZ were also unsuccessful cases. These
ﬁndings are supported by another study in dogs with
status epilepticus, which reported a signiﬁcantly
worse outcome associated with MUO and focal status
epilepticus.5 Therefore, IN-MDZ appears a more eﬀec-
tive ﬁrst-line management option for idiopathic epilepsy
cases rather than those dogs with underlying neoplasia
or MUO. IN-MDZ was not evaluated for reactive sei-
zures because immediate etiological treatment is usually
needed for these cases (e.g, glucose for hypoglycemic
cases) to abolish seizure activity; a fact that could have
inﬂuenced the apparent drug eﬃcacy and the results of
this study.
The safety of IN-MDZ has been evaluated in humans
with emergency seizures, and it was reported to be a
safe drug without signiﬁcant adverse eﬀects. In one
study, mild adverse eﬀects including vomiting, hypoxia,
and excessive drowsiness were reported for both
IN-MDZ and R-DZP.26 However, R-DZP resulted in
more adverse eﬀects compared to the IN-MDZ group.
In another study,33 IN-MDZ was compared to IV DZP
and although mild hypertension, bradycardia and
hypoxia occurred in some adults and children in both
groups, no signiﬁcant complications were reported. In
the current clinical trial, severe progressive sedation and
ataxia was reported in all the dogs, regardless of the
drug administered. However, these signs could equally
be attributed to the postictal phase and severe seizure
activity (for the period within the ﬁrst 10 minutes after
drug administration), or a postictal phase and other
AEDs used (for the period after the ﬁrst 10 minutes),
and were all self-limiting. No cardiovascular or respira-
tory dysfunction (e.g, no increased risk of aspiration
pneumonia or similar) or hypoxia was reported in these
cases.
In terms of ease of administration, a previous study
reported no diﬃculties in 90% (27 of 30) of patients
relating to IN administration of MDZ.33 In the current
study, diﬃculties were reported in 45% of the cases but
were mild and included brief sneezing during adminis-
tration or diﬃculty in applying the device to the small
nostrils of some dogs. These could potentially lead to
leakage of a small amount of the drug out of the nasal
cavity, although this was not speciﬁcally reported as an
issue in these cases. The atomized form of the drug is
also less likely to overﬂow out of the nostrils compared
to liquid forms.
The anatomic structures of the nasal cavity as well as
the physiological and pharmacokinetic mechanisms of
the IN administration of drugs might provide an expla-
nation for the eﬀectiveness of IN-MDZ. The nasal
(sub)mucosa provides a large, highly vascular absorp-
tive surface adjacent to the brain and oﬀers a direct
pathway for drug absorption into the bloodstream,
avoiding the ﬁrst-pass hepatic metabolism.49–51 This is
advantageous for benzodiazepines that need to rapidly
accumulate in the brain during emergency management
of seizures, but have a relatively short latency of action
and undergo extensive hepatic metabolism. MDZ is
absorbed by the (sub)mucosal nasal vessels and enters
the central nervous system by crossing the blood-brain
barrier, with a rapid clinical eﬀect.47 In addition, based
on laboratory animal and human studies, some drugs,
including benzodiazepines, might be able to reach the
brain directly via the olfactory and trigeminal neural
pathways.50–56 The latter might be quite advantageous
for refractory cases, where there is inadequate penetra-
tion of AEDs across the BBB due to overexpression of
drug vascular transporters such as P-glycoprotein.57
These pharmacological advantages of IN administration
of MDZ allow the drug to reach the systemic circula-
tion more rapidly and may make it more eﬀective in
controlling emergency seizures with a lower “seizure
cessation” time compared to the rectally administered
drugs.
A mucosal atomization device was chosen in this
study over a plain syringe for the IN drug administra-
tion because atomization of a liquid medication has
been suggested to provide the beneﬁt of increased and
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more rapid absorption.58–60 The absorption rate and
plasma concentration of drugs delivered by atomization
has been suggested to be comparable to IV administra-
tion in some studies.53,61,62 In humans, this delivery
method also results into a broader distribution of the
medication across the nasal mucosa, an increased
bioavailability, and improved time to onset and eﬃcacy
of the drug with regard to seizure cessation.18 Finally,
because the medication is atomized as a mist, it is less
likely to overﬂow out of the nasal cavity compared to
administration as a liquid form.53,61,62 Indeed, in the
current study, the MAD provided a simple and quick
method for administering the medication. The soft
edge of the device, which is in direct contact with the
nostrils and the entrance of the nasal cavity, prevents
expulsion of the drug and injuries to the soft tissues
that could occur with the hard tip of a plain syringe in
seizuring animals experiencing severe motor activity.
The use of the MAD may have contributed toward the
increased eﬀectiveness of IN-MDZ in this study,
although this cannot be conﬁrmed, as administration
with the MAD was not compared to a plain syringe
for IN administration of the medication. Lastly,
slightly more time was needed to prepare the IN-MDZ
(29 seconds) compared to R-DZP (16 seconds), which
was attributed to the use of the MAD in the IN-MDZ
group. However, doctor and owner’s familiarization
with the device would be expected to reduce the time
of preparation and minimize any delays in administra-
tion.
This is the ﬁrst randomized parallel-group clinical
trial evaluating the eﬀectiveness of IN-MDZ for ceas-
ing status epilepticus in dogs; however, there are a few
study limitations that should be considered. Firstly, it
was an open-label trial, which could introduce a risk
of bias toward either medication. However, a random-
ization procedure and objective assessment methods
(e.g, recording times by the use of a stop-watch) were
used to reduce this possibility as far as possible. Sec-
ondly, the number of included dogs per group was
not particularly large, and although a statistically sig-
niﬁcant result could be obtained, these results should
be also conﬁrmed by a larger trial. Despite this initial
sample size calculation, due to the diﬃculty to gather
status epilepticus cases and the fact that the calcula-
tion was based on human data rather than canine
data, an interim analysis was performed. The interim
analysis showed that there was already a signiﬁcant
result, and therefore, it was thought that it was uneth-
ical to continue the trial. Similar approach was fol-
lowed in another study.63 There was also a diﬀerence
in the size of the 2 groups, but this was attributed to
the fact that this study was multi-institutional and a
few centers could not complete the envelope numeric
series at the time of trial’s termination. Thirdly, dogs
that have been seizuring for periods longer than
5 minutes might have developed some degree of phar-
macoresistance toward either medication. However,
there was a relatively equal distribution of such cases
in each group that could aﬀect the eﬀectiveness of
both drugs in a similar manner. Lastly, only speciﬁc
doses of each drug were tested and therefore higher or
lower MDZ and DZP doses could result in diﬀerent
outcomes. In terms of the DZP dose, in particular,
this can also depend on the concurrent administration
of phenobarbital. However, the majority of these dogs
were not receiving phenobarbital, and therefore, these
results are less likely to have been impacted by this
factor.
Conclusion
IN-MDZ might be an eﬀective, quick, and safe
ﬁrst-line medication for controlling canine status
epilepticus and appears superior to R-DZP. The
results support the use of IN-MDZ for treating emer-
gency seizures, in particular idiopathic epilepsy cases,
before IV access. These ﬁndings could be extrapolated
to treatment of emergency seizures at home before
hospital admission.
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